Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-15 19:58:26 EDT

PhotosVideosAllPeople
LatestRanked
@lightningduck.bsky.socialOct 15, 2026, 9:25 PM

#ChronicIllness #MultipleSclerosis

Photo, no descriptionPhoto, no description
@msnewstoday.bsky.socialOct 15, 2026, 7:23 PM

Explore the details: https://bit.ly/4jq1eUD

Higher OCB counts in newly diagnosed MS were linked to broader MRI lesion spread and poorer verbal learning and memory.

#MultipleSclerosis #MS #MultipleSclerosisNewsToday #Bionews

@msnewstoday.bsky.socialOct 15, 2026, 5:38 PM

Get the scoop: https://bit.ly/4dF2WxI

Thinning of a layer of nerve cells in the eye's retina was associated with slower cognitive processing in people with MS, per a study.

#MultipleSclerosis #MS #MultipleSclerosisNewsToday #Bionews

@msnewstoday.bsky.socialOct 15, 2026, 3:45 PM

Take a closer look: https://bit.ly/4i0Zjn9

Like Bilbo Baggins, columnist Ben Hofmeister has "things to do," and says it is time to say farewell to his excellent and admirable readers.

#MultipleSclerosis #MS #MultipleSclerosisNewsToday #Bionews

@ijmsc.bsky.socialOct 15, 2026, 1:45 PM

Falls involve many factors at once. In this qualitative study, 25 PwMS were interviewed soon after their falls (94 total). The authors suggest taking a broader fall history and building rehab around each person, so they can better judge their risk.
doi.org/10.7224/1537...
#MultipleSclerosis #falls

Photo, no description
@palamedesreport.orgOct 15, 2026, 1:00 PM

Ofatumumab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Nationwide Cohort Study.
Neurology

This week in Multiple Sclerosis and Neuroimmunology: palamedesreport.org/this-week/multiple-sclerosis
pubmed.ncbi.nlm.nih.gov/42832743

#MedSky #neurology #multiplesclerosis

This week in Multiple Sclerosis and Neuroimmunology: Ofatumumab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Nationwide Cohort Study. Neurology. AI-generated. Verify against the paper. In Danish registry patients with relapsing-remitting MS, ofatumumab was associated with a marginally higher annualized relapse rate than ocrelizumab (rate ratio 1.65, 95% CI 1.09-2.50, p = 0.018), though ARRs were very low with both. Design: Observational cohort study using the Danish Multiple Sclerosis Registry; 1,870 patients initiating treatment January 2022 to November 2025; inverse probability of treatment weighting on propensity scores; intention-to-treat main analyses with per-protocol analyses; median follow-up 2.0 years (IQR 1.3-2.7) ofatumumab, 2.5 years (1.3-3.4) ocrelizumab. Class II evidence. Population: Patients with relapsing-remitting MS: 485 started ocrelizumab (mean age 41.1 years, 65.2% female) and 1,385 started ofatumumab (mean age 41.3 years, 72.0% female). Biomarker status not reported. Ranked by PubMed attention — the views of everyone using PubMed — not by quality, importance or correctness.
@gregoryai.bsky.socialOct 15, 2026, 7:00 AM

Multiple sclerosis (MS) is a persistent immune-mediated condition marked by neuroinflammation, demyelination, and ongoing neurological impairment. Although there have been advancements in therapies aimed at modifying the disease, signifi...
#MSchat #MS #Neurology #MultipleSclerosis #NeuroSky #MedSky

@morethanms.bsky.socialOct 15, 2026, 2:30 AM

A common symptom of multiple sclerosis is brain fog.

But brain fog isn’t as easy to describe.

It’s multifaceted. Unpredictable. You learn to adapt, but it’s still a quagmire.

Brain fog doesn’t always feel like fog.

Sometimes it feels like certainty.

#MultipleSclerosis #MS #BrainFog #BrainHealth

@kevjbyrne.bsky.socialOct 14, 2026, 11:42 PM

An abundance of caution is on hold while I demonstrate my need for your donations and support. Garage Dayz October, pt. 2 is tomorrow! #NeverStopNeverQuitForThem #MultipleSclerosis #MS #nationalmssociety #CanYouTRK

@kevjbyrne.bsky.socialOct 14, 2026, 11:15 PM

Cleared by my doctor, provided I assume an abundance of caution. Let’s see how this goes! #NeverStopNeverQuitForThem #MultipleSclerosis #MS #nationalmssociety #CanYouTRK

@newsramp.comOct 14, 2026, 9:00 PM

Quantum BioPharma (NASDAQ: QNTM) receives FDA clearance to begin Phase 2 trials for Lucid-MS, a novel multiple sclerosis therapy that protects nerve cells by targeting myelin damage — not the immune system. A potentially distinct approach to MS treatment. #MultipleSclerosis #Biopharma

Image from article
@neurologyadvisor.bsky.socialOct 14, 2026, 8:58 PM

Explore the key research topics and clinical advances that will shape discussions at #MSToronto2026, the joint ACTRIMS/ECTRIMS meeting on MS and related disorders.

#MultipleSclerosis

https://bit.ly/4zwE0AX

@msnewstoday.bsky.socialOct 14, 2026, 3:46 PM

Get the scoop: https://bit.ly/4yKBqHx

Briumvi may be more effective than Kesimpta or Ocrevus at preventing disability progression in relapsing MS, an indirect comparison shows.

#MultipleSclerosis #MS #MultipleSclerosisNewsToday #Bionews

@abudd.bsky.socialOct 14, 2026, 1:59 PM

multiplesclerosisnewstoday.com/news-posts/2...
#MultipleSclerosis

@abudd.bsky.socialOct 14, 2026, 1:58 PM

multiplesclerosisnewstoday.com/columns/2026...
#MultipleSclerosis

@killbaitaustralia.bsky.socialOct 14, 2026, 2:20 AM

Selma Blair released on bail after pleading not guilty to assault charges following in-flight incident

🤖 IA: It's not clickbait ✅
👥 Users: It's not clickbait ✅

#assault #flightincident #multiplesclerosis

👇👇👇

@wheelieoutthere.bsky.socialOct 14, 2026, 1:29 AM

Ask an MS Expert Video — Managing #Depression With MS — about half of people w #MultipleSclerosis experience it
Learn coping strategies & treatments to help manage depression w Dr. Anthony Feinstein, professor of psychiatry at Univ. of Toronto, specializing in MS.
Prerecorded: tinyurl.com/3tazdjxc

@morethanms.bsky.socialOct 14, 2026, 12:19 AM

miguelallamani.com/tuesday-play...

The Tuesday Playbook is live. Get into it, people.

Ordinary life with MS. Short, usable pieces by someone with brain fog, for people who know what it’s like to lose their place.

Take what fits. Share it.

#MultipleSclerosis #BrainFog

@msnewstoday.bsky.socialOct 14, 2026, 12:11 AM

Discover more: https://bit.ly/4hL90Hy

Reduced immune responses to the Epstein-Barr virus may help explain the efficacy of anti-CD20 therapy in people with MS, per a study.

#MultipleSclerosis #MS #MultipleSclerosisNewsToday #Bionews

@kevjbyrne.bsky.socialOct 13, 2026, 11:11 PM

The verdict is on my foot, kind of… #NeverStopNeverQuitForThem #MultipleSclerosis #MS #nationalmssociety #CanYouTRK

Load more